statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Buy" by Analysts

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been given an average recommendation of "Buy" by the six research firms that are covering the company, MarketBeat...

Q4 2023 Rani Therapeutics Holdings Inc Earnings Call Transcript

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript...

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1...

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ( Rani Therapeutics or Rani ) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) stock price dropped 11% last week; private companies would not be happy

Key Insights Rani Therapeutics Holdings' significant private companies ownership suggests that the key decisions are...

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)

Pharmacokinetics of Ustekinumab (CT-P43) Oral (RT-111) vs SC Injection

 Pharmacokinetics of Ustekinumab (CT-P43) Oral (RT-111) vs SC Injection

- RT-111 achieved high...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Volume	47,157.00
52-Wk High	$8.75
52-Wk Low	$1.82

RANI Rani Therapeutics Holdings Inc - Ordinary Shares Class A

About

Feed

News

Earnings

Fundamentals